Although there are many drugs targeting HER-2-positive breast cancer, such as the humanized monoclonal antibody trastuzumab and the HER-2 kinase inhibitor lapatinib, poor prognosis and high drug resistance still threaten the lives of HER-2-positive breast cancer patients 4. Here, ERBB2 is linked to breast cancer.